
STATUS UPDATE:

**UPDATES ON VARIOUS LITIGATION PROCEEDINGS IN
THE PEOPLE'S REPUBLIC OF CHINA**

1. Proceedings commenced by Health Kind International (Shanghai) Limited (上海医霖医院投资管理咨询有限公司) (also referred to as “Healthkind Investment Management Consulting Co. Ltd.”) (“Health Kind Shanghai”)

As announced previously on 5 December 2018, 29 January 2019, 31 May 2019, 28 June 2019 and 30 July 2019, Health Kind Shanghai, a subsidiary of the Company, commenced legal proceedings before the Shanghai No. 1 Intermediate Court against David Lin and Weixin Hospital Investment Management (Shanghai) Co. Ltd (卫心医院投资管理(上海)有限公司) (“Weixin”), seeking the return of 100% of the shares in Wuxi New District Phoenix Hospital Co., Ltd (无锡新区凤凰医院有限责任公司) (“Wuxi Co”). In these proceedings, Health Kind Shanghai contends that David Lin breached his fiduciary duties in causing Health Kind Shanghai to enter into rescission agreements on 8 November 2013 to transfer away Health Kind Shanghai’s shares in Wuxi Co to Shanghai Yilin Medical Management Consulting Co., Ltd (上海医霖医疗管理咨询有限公司) (“Shanghai Yilin”), and thereafter caused Shanghai Yilin to transfer the same shares to Weixin.

On 14 October 2019, the Company was informed that the Shanghai No. 1 Intermediate Court dismissed Health Kind Shanghai’s claim against David Lin and Weixin. The Company has instructed PRC legal counsel to file an appeal, and to vigorously advance the Company’s position.

In the meantime, as announced on 5 December 2018 and 29 January 2019, 100% of the shares in Wuxi Co. (which has a registered capital of RMB 44,000,000) remains frozen by the Shanghai No. 1 Intermediate Court from 30 November 2018 to 29 November 2021.

2. Proceedings commenced by Wuxi Yilin Health Management Co. Ltd (无锡医霖健康管理公司) (“Wuxi Yilin Health”)

As announced previously on 5 December 2018 and 29 January 2019, Wuxi Yilin Health, a subsidiary of the Company, has commenced legal proceedings against David Lin before the Wuxi Intermediate Court. In these proceedings, it is contended that David Lin breached his fiduciary duties to Wuxi Yilin Health, by causing Wuxi Yilin Health to enter into a commitment letter dated 28 July 2014, wherein it agreed that, inter alia, 1) the capital injection of Wuxi Yilin Health would not entail any shareholding interest in Wuxi Co.; and 2) Wuxi Yilin Health would not object if Shanghai Yilin transfers the shares of Wuxi Co.

On 14 October 2019, the Company was informed that the Wuxi Intermediate Court delivered its judgment, and dismissed Wuxi Yilin Health’s claim against David Lin. The Company has instructed its PRC legal counsel to file an appeal, and to vigorously advance the Company’s position.

OUE Lippo Healthcare Limited

Company Registration No. 201304341E

(In receivership over charged shares in certain subsidiaries)

6 Shenton Way, #10-09A, OUE Downtown 2, Singapore 068809

T: +65 6578 9188 F: 64794647 www.ouelh.com

The Company will provide further updates on the status of the above matters through SGXNET in accordance with the requirements under the applicable Catalist Rules.

By Order of the Board
OUE Lippo Healthcare Limited

Mr. Yet Kum Meng
Chief Executive Officer and Executive Director
14 October 2019

*This announcement has been prepared by the Company and its contents have been reviewed by the Company's sponsor, PrimePartners Corporate Finance Pte. Ltd. (the "**Sponsor**"), in accordance with Rules 226(2)(b) and 753(2) of the Singapore Exchange Securities Trading Limited (the "**SGX-ST**") Listing Manual Section B: Rules of Catalist.*

This announcement has not been examined or approved by the SGX-ST. The SGX-ST assume no responsibility for the contents of this announcement, including the correctness of any of the statements or opinions made or reports contained in this announcement.

The contact person for the Sponsor is Ms Gillian Goh, Director, Head of Continuing Sponsorship (Mailing address: 16 Collyer Quay, #10-00 Income at Raffles, Singapore 049318 and E-mail: sponsorship@ppcf.com.sg).